SCHEMBL4469579

SCHEMBL4469579

Cc1csc(N2CCCCC2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
AR P10275 1/20 0.53
TP53 P04637 1/20 0.53
ALOX15 P16050 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RAB9A P51151 2/20 0.50
DPP4 P27487 1/20 0.48
MEN1 O00255 3/20 0.47
POLB P06746 3/20 0.45
LMNA P02545 2/20 0.45
KMT2A Q03164 2/20 0.45
HRH3 Q9Y5N1 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
BLM P54132 1/20 0.45
ESR2 Q92731 1/20 0.45
PIK3CG P48736 1/20 0.45
NPC1 O15118 1/20 0.44
OGA O60502 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3511935 0.98 L3MBTL1 (0.54) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL4472290 0.94 L3MBTL1 (0.54) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL3551633 0.84 ALDH1A1 (0.49) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL9794796 0.84 L3MBTL1 (0.46) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL9794803 0.83 BAZ2A (0.48) SMN1; SMN2L3MBTL1DPP4MEN1HRH3
SCHEMBL6929063 0.82 ALDH1A1 (0.54) SMN1; SMN2L3MBTL1RAB9ADPP4MEN1
SCHEMBL1713003 0.82 L3MBTL1 (0.47) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL9794819 0.82 L3MBTL1 (0.47) SMN1; SMN2L3MBTL1ARTP53ALOX15
SCHEMBL4463690 0.81 LMNA (0.68) SMN1; SMN2ARRAB9AMEN1LMNA
SCHEMBL2228747 0.81 BAZ2A (0.49) SMN1; SMN2L3MBTL1DPP4MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912708-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-02-27 US disclosed
US-8207337-B2 Reagent for organic synthesis reaction containing organic triol borate salt WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-06-26 US disclosed
US-8207337-B2 Reagent for organic synthesis reaction containing organic triol borate salt WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-06-26 US disclosed
US-7888363-B2 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-15 US disclosed
US-20100087646-A1 REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-08 US disclosed
US-20100087646-A1 REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-08 US disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 US disclosed
US-7351720-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-04-01 US disclosed
US-20070142380-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 US disclosed
US-7173137-B2 Epothilone analogs THE SCRIPPS RESEARCH INSTITUTE (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912708-B2 Macrocyclic heterocycles and uses thereof HRAS, KRAS, TP53 SMN1; SMN2 1539/4885L3MBTL1 2631/4885AR 1036/4885
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 SMN1; SMN2 3258/4885L3MBTL1 1736/4885AR 510/4885
US-20070142380-A1 Viral Polymerase Inhibitors POLM, POLR2H, POLR2A SMN1; SMN2 1649/4885L3MBTL1 203/4885AR 2253/4885
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ACKR3, CCR7, CCR2 SMN1; SMN2 4441/4885L3MBTL1 4872/4885AR 2232/4885
US-20100087646-A1 REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT ORC3, OXSR1, OSTC SMN1; SMN2 3837/4885L3MBTL1 1985/4885AR 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.